News | Antiplatelet and Anticoagulation Therapies | April 18, 2019

Study Finds Only Six Percent of Patients Taking Statins as Directed

Researchers suggest patients are non-compliant due to feeling overwhelmed, even though statins cut risk of second major adverse cardiovascular event in half

Study Finds Only Six Percent of Patients Taking Statins as Directed

April 18, 2019 — A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse cardiovascular event by almost 50 percent, if they adhere to taking a statin medication as prescribed by their doctors.

The bad news, however, is that researchers from the Intermountain Healthcare Heart Institute in Salt Lake City found that only about 6 percent of patients are in fact following the statin regimen given to them to lower their cholesterol, negating any potential cardiovascular benefits.

“A lot of clinical trials have shown that statins reduce the risk of secondary outcomes, so it’s really important that they take these medications,” said the study’s principal investigator, Heidi May, Ph.D., principal investigator of the study, and cardiovascular epidemiologist at the Intermountain Healthcare Heart Institute. “The surprising thing that we found is that so few patients, even within an insured population, just didn’t take their statin medication as prescribed.”

Results of the study were presented at the American College of Cardiology (ACC) Scientific Sessions, March 16-18 in New Orleans.

In the study, researchers identified 5,468 patients first diagnosed with atherosclerotic cardiovascular disease between 1999 and 2013. These patients received a statin prescription to reduce their cholesterol within the first 12 months of diagnosis. Researchers then looked at two things: whether or not the patients took their medication, and how many major adverse clinical events (stroke, heart attack or death) they had over the next five years.

They found that patients with optimal adherence — who took their statins as prescribed at least 80 percent of the time — reduced their risk of dying or having a heart attack or stroke by nearly 50 percent. Unfortunately, though, only 351 out of those 5,468 patients fell into the optimal adherence category — which is about 6 percent.

Researchers also found that 25 percent of patients never filled their statin prescription in the first place, and 25 percent did not fill their second one.

Researchers think there are several reasons for non-adherence, including:

  • A bias against statins;

  • Concern that they’re already taking too many medications;

  • Worry about side-effects;

  • The incorrect belief that after a few years on statins, they are cured and do not need to take them anymore; or

  • They are just not that important.

The cost of the drugs is most likely not a factor, researchers say, since all of the patients in the study were enrolled in SelectHealth insurance, and the statins cost them only about $10 for a 90-day supply.

May believes the importance of taking statins could be lost in the abundance of information patients are given at discharge.

“During this time, patients most likely don’t feel their best, they’re probably scared about what just happened to them and nervous about their future. They may not be able to process everything that’s happening and how to best follow up,” she said.

May added that the findings of the study should help caregivers see how crucial it is to ensure their patients who are being discharged understand the importance of the medication, and that continual education needs to be provided about the importance of taking their medications as prescribed.

“The patients should be asked about whether or not they’re taking their statin at their follow-up appointments, especially soon after discharge,” May said.

For the study, researchers from Intermountain Healthcare collaborated with The Medicines Company.

“This is important research to better understand the real-world treatment of atherosclerotic cardiovascular disease, and to validate the benefits of statins as proven first-line therapy and the challenges associated with poor adherence,” said May. “We appreciate our collaboration with The Medicines Company. They share our commitment to improving cardiovascular care for patients.”

Study funding was provided by donors to the Intermountain Research and Medical Foundation.

For more information: www.acc.org

Related Content

Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
News | ACC
February 15, 2022 — The American College of Cardiology’s Cardiovascular Summit Virtual (CV Summit) will feature three ...
Home February 15, 2022
Home
Subscribe Now